Integral Molecular, a leader in antibody discovery and protein engineering, has launched a new technology-based service to ...

Myasthenia gravis (MG) results from autoimmune antibodies against the post-synaptic neuromuscular junction with three major ...

This platform gives access to an expanded complementary determining region (CDR) diversity that allows for rapid discovery of antibodies against (i) therapeutically relevant epitopes, (ii ...

Additionally, it provides LucinaTech, an antibody humanization to identify framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; antibody ...

BI 771716, engineered using CDR-Life's proprietary technology and developed by Boehringer Ingelheim, represents a potential breakthrough in retinal therapy. Its unique antibody fragment design ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

The O-specific polysaccharide of Klebsiella pneumoniae in patients with bloodstream infections is immunogenic, and its closely related subtypes are cross-reactive.

Paratope-PLUS™ involves mutating each residue of an antibody's CDRs (Complementarity Determining Regions) to all 19 other amino acids, identifying every variant that retains or enhances function.